PT4053118T - Composto cíclico fundido heterocíclico substituído, método de preparação deste e utilização farmacêutica deste - Google Patents
Composto cíclico fundido heterocíclico substituído, método de preparação deste e utilização farmacêutica desteInfo
- Publication number
- PT4053118T PT4053118T PT208820399T PT20882039T PT4053118T PT 4053118 T PT4053118 T PT 4053118T PT 208820399 T PT208820399 T PT 208820399T PT 20882039 T PT20882039 T PT 20882039T PT 4053118 T PT4053118 T PT 4053118T
- Authority
- PT
- Portugal
- Prior art keywords
- preparation
- substituted heterocyclic
- method therefor
- cyclic compound
- pharmaceutical use
- Prior art date
Links
- 150000001923 cyclic compounds Chemical class 0.000 title 1
- 125000000623 heterocyclic group Chemical group 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911045542 | 2019-10-30 | ||
| CN202010272563 | 2020-04-09 | ||
| CN202011140832 | 2020-10-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT4053118T true PT4053118T (pt) | 2024-12-05 |
Family
ID=75715785
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT208820399T PT4053118T (pt) | 2019-10-30 | 2020-10-28 | Composto cíclico fundido heterocíclico substituído, método de preparação deste e utilização farmacêutica deste |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US12054497B2 (pt) |
| EP (2) | EP4053118B1 (pt) |
| JP (2) | JP7601869B2 (pt) |
| KR (1) | KR20220106765A (pt) |
| CN (3) | CN117645614A (pt) |
| AU (1) | AU2020374844C1 (pt) |
| BR (1) | BR112022008375A2 (pt) |
| CA (1) | CA3156777A1 (pt) |
| DK (1) | DK4053118T3 (pt) |
| ES (1) | ES3000619T3 (pt) |
| FI (1) | FI4053118T3 (pt) |
| HR (1) | HRP20241590T1 (pt) |
| PT (1) | PT4053118T (pt) |
| RS (1) | RS66320B1 (pt) |
| TW (1) | TWI754438B (pt) |
| WO (1) | WO2021083167A1 (pt) |
| ZA (1) | ZA202205758B (pt) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019217307A1 (en) | 2018-05-07 | 2019-11-14 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| US12208099B2 (en) | 2018-09-10 | 2025-01-28 | Mirati Therapeutics, Inc. | Combination therapies |
| EP3871673B1 (en) | 2018-10-26 | 2024-01-03 | Taiho Pharmaceutical Co., Ltd. | Novel indazole compound or salt thereof |
| EP3908283A4 (en) | 2019-01-10 | 2022-10-12 | Mirati Therapeutics, Inc. | KRAS G12C INHIBITORS |
| WO2021041671A1 (en) | 2019-08-29 | 2021-03-04 | Mirati Therapeutics, Inc. | Kras g12d inhibitors |
| US12122787B2 (en) | 2019-09-20 | 2024-10-22 | Shanghai Jemincare Pharmaceuticals Co., Ltd | Fused pyridone compound, and preparation method therefor and use thereof |
| CN119462689A (zh) * | 2019-09-20 | 2025-02-18 | 上海济煜医药科技有限公司 | 稠合吡啶酮类化合物及其制备方法和应用 |
| WO2021061749A1 (en) | 2019-09-24 | 2021-04-01 | Mirati Therapeutics, Inc. | Combination therapies |
| US11697657B2 (en) | 2019-10-28 | 2023-07-11 | Merck Sharp & Dohme Llc | Small molecule inhibitors of KRAS G12C mutant |
| DK4053118T3 (da) * | 2019-10-30 | 2024-11-25 | Genfleet Therapeutics Shanghai Inc | Substitueret heterocyklisk kondenseret cyklisk forbindelse, fremgangsmåde til fremstilling deraf og farmaceutisk anvendelse deraf |
| MX2022007515A (es) | 2019-12-20 | 2022-09-19 | Mirati Therapeutics Inc | Inhibidores de sos1. |
| JP2023539188A (ja) * | 2020-08-21 | 2023-09-13 | 浙江海正薬業股▲ふん▼有限公司 | 四環系誘導体、その製造方法及びその医薬用途 |
| CN115916778A (zh) * | 2020-09-12 | 2023-04-04 | 赛诺哈勃药业（成都）有限公司 | 甲硫氨酸腺苷转移酶抑制剂、其制备方法及应用 |
| MX2023003338A (es) | 2020-09-23 | 2023-06-14 | Erasca Inc | Piridonas y pirimidonas tricíclicas. |
| US20230107642A1 (en) | 2020-12-18 | 2023-04-06 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| TW202246267A (zh) * | 2021-03-25 | 2022-12-01 | 大陸商上海濟煜醫藥科技有限公司 | 稠合吡啶酮類化合物鹽型、晶型及其應用 |
| CN115124533A (zh) * | 2021-03-26 | 2022-09-30 | 浙江海正药业股份有限公司 | 四环类衍生物、其制备方法和其医药上的用途 |
| CN116848111A (zh) * | 2021-03-26 | 2023-10-03 | 浙江海正药业股份有限公司 | 一种kras抑制剂关键中间体及其制备方法 |
| WO2022206723A1 (zh) * | 2021-03-30 | 2022-10-06 | 浙江海正药业股份有限公司 | 杂环类衍生物、其制备方法及其医药上的用途 |
| WO2022223037A1 (zh) * | 2021-04-22 | 2022-10-27 | 劲方医药科技(上海)有限公司 | Kras抑制剂的盐或多晶型物 |
| AU2022314009A1 (en) * | 2021-07-23 | 2024-01-25 | Suzhou Zanrong Pharma Limited | Kras g12d inhibitors and uses thereof |
| EP4455147A1 (en) * | 2021-12-24 | 2024-10-30 | Genfleet Therapeutics (Shanghai) Inc. | Polymorph of kras inhibitor, preparation method therefor, and use thereof |
| CN116327956A (zh) * | 2022-04-01 | 2023-06-27 | 劲方医药科技(上海)有限公司 | 药物组合物、其用途及癌症的治疗方法 |
| WO2024061267A1 (zh) * | 2022-09-21 | 2024-03-28 | 劲方医药科技(上海)有限公司 | 一种药物组合物及其制备方法和用途 |
| WO2024081674A1 (en) | 2022-10-11 | 2024-04-18 | Aadi Bioscience, Inc. | Combination therapies for the treatment of cancer |
| WO2025036442A1 (zh) * | 2023-08-15 | 2025-02-20 | 劲方医药科技(上海)股份有限公司 | 吡嗪并萘啶二酮类化合物的制备方法及其中间体 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3962445A (en) * | 1973-05-19 | 1976-06-08 | Beecham Group Limited | Anti-allergenic carbostyril derivatives |
| GB201216017D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Inhibitor compounds |
| JP6559123B2 (ja) * | 2013-10-10 | 2019-08-14 | アラクセス ファーマ エルエルシー | Ｋｒａｓｇ１２ｃの阻害剤 |
| JO3805B1 (ar) | 2013-10-10 | 2021-01-31 | Araxes Pharma Llc | مثبطات كراس جي12سي |
| GB201406486D0 (en) * | 2014-04-10 | 2014-05-28 | Redx Pharma Ltd | Antibacterial compounds |
| EP3177593A1 (en) * | 2014-08-06 | 2017-06-14 | Novartis AG | Quinolone derivatives as antibacterials |
| JOP20190272A1 (ar) * | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
| AU2018329920B2 (en) | 2017-09-08 | 2022-12-01 | Amgen Inc. | Inhibitors of KRAS G12C and methods of using the same |
| BR112020009818A2 (pt) | 2017-11-15 | 2020-11-03 | Mirati Therapeutics, Inc. | inibidores kras g12c |
| WO2019110751A1 (en) * | 2017-12-08 | 2019-06-13 | Astrazeneca Ab | Tetracyclic compounds as inhibitors of g12c mutant ras protein, for use as anti-cancer agents |
| CA3098574A1 (en) | 2018-05-04 | 2019-11-07 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| JP2022517446A (ja) * | 2018-12-25 | 2022-03-09 | 青島優梦家居科技有限公司 | 枕 |
| CN113396147B (zh) * | 2019-05-31 | 2024-06-18 | 上海翰森生物医药科技有限公司 | 芳香杂环类衍生物调节剂、其制备方法和应用 |
| CN112300194B (zh) | 2019-07-30 | 2022-01-14 | 上海凌达生物医药有限公司 | 一类稠环吡啶酮类化合物、制备方法和用途 |
| CN112300196A (zh) | 2019-07-30 | 2021-02-02 | 上海凌达生物医药有限公司 | 一类哌啶稠环类化合物、制备方法和用途 |
| CN119462689A (zh) | 2019-09-20 | 2025-02-18 | 上海济煜医药科技有限公司 | 稠合吡啶酮类化合物及其制备方法和应用 |
| US12122787B2 (en) * | 2019-09-20 | 2024-10-22 | Shanghai Jemincare Pharmaceuticals Co., Ltd | Fused pyridone compound, and preparation method therefor and use thereof |
| DK4053118T3 (da) * | 2019-10-30 | 2024-11-25 | Genfleet Therapeutics Shanghai Inc | Substitueret heterocyklisk kondenseret cyklisk forbindelse, fremgangsmåde til fremstilling deraf og farmaceutisk anvendelse deraf |
-
2020
- 2020-10-28 DK DK20882039.9T patent/DK4053118T3/da active
- 2020-10-28 EP EP20882039.9A patent/EP4053118B1/en active Active
- 2020-10-28 HR HRP20241590TT patent/HRP20241590T1/hr unknown
- 2020-10-28 FI FIEP20882039.9T patent/FI4053118T3/fi active
- 2020-10-28 WO PCT/CN2020/124226 patent/WO2021083167A1/zh unknown
- 2020-10-28 BR BR112022008375A patent/BR112022008375A2/pt unknown
- 2020-10-28 JP JP2022526049A patent/JP7601869B2/ja active Active
- 2020-10-28 CN CN202311339164.2A patent/CN117645614A/zh active Pending
- 2020-10-28 CN CN202080034074.0A patent/CN113853373B/zh active Active
- 2020-10-28 EP EP23204050.1A patent/EP4328229A3/en active Pending
- 2020-10-28 CA CA3156777A patent/CA3156777A1/en active Pending
- 2020-10-28 KR KR1020227018301A patent/KR20220106765A/ko active Pending
- 2020-10-28 PT PT208820399T patent/PT4053118T/pt unknown
- 2020-10-28 ES ES20882039T patent/ES3000619T3/es active Active
- 2020-10-28 RS RS20241407A patent/RS66320B1/sr unknown
- 2020-10-28 CN CN202210818001.1A patent/CN115057872B/zh active Active
- 2020-10-28 AU AU2020374844A patent/AU2020374844C1/en active Active
- 2020-10-28 US US17/773,607 patent/US12054497B2/en active Active
- 2020-10-29 TW TW109137617A patent/TWI754438B/zh active
-
2022
- 2022-05-16 ZA ZA2022/05758A patent/ZA202205758B/en unknown
-
2023
- 2023-10-11 JP JP2023176319A patent/JP2023175993A/ja active Pending
- 2023-10-17 US US18/381,121 patent/US20240158417A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023502891A (ja) | 2023-01-26 |
| CN115057872A (zh) | 2022-09-16 |
| TWI754438B (zh) | 2022-02-01 |
| JP7601869B2 (ja) | 2024-12-17 |
| US20240158417A1 (en) | 2024-05-16 |
| BR112022008375A2 (pt) | 2022-07-12 |
| FI4053118T3 (fi) | 2024-11-25 |
| KR20220106765A (ko) | 2022-07-29 |
| EP4053118B1 (en) | 2024-10-09 |
| EP4053118A1 (en) | 2022-09-07 |
| CA3156777A1 (en) | 2021-05-06 |
| AU2020374844A1 (en) | 2022-06-16 |
| EP4328229A2 (en) | 2024-02-28 |
| RS66320B1 (sr) | 2025-01-31 |
| LT4053118T (pt) | 2024-12-10 |
| HRP20241590T1 (hr) | 2025-01-31 |
| CN117645614A (zh) | 2024-03-05 |
| ZA202205758B (en) | 2023-02-22 |
| AU2020374844B2 (en) | 2024-01-25 |
| EP4053118A4 (en) | 2023-01-04 |
| US12054497B2 (en) | 2024-08-06 |
| JP2023175993A (ja) | 2023-12-12 |
| CN113853373B (zh) | 2022-08-05 |
| DK4053118T3 (da) | 2024-11-25 |
| US20230084095A1 (en) | 2023-03-16 |
| CN113853373A (zh) | 2021-12-28 |
| CN115057872B (zh) | 2025-03-18 |
| EP4328229A3 (en) | 2024-10-02 |
| AU2020374844C1 (en) | 2024-07-25 |
| WO2021083167A1 (zh) | 2021-05-06 |
| ES3000619T3 (en) | 2025-03-03 |
| TW202128701A (zh) | 2021-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202205758B (en) | Substituted heterocyclic fused cyclic compound, preparation method therefor and pharmaceutical use thereof | |
| IL291467A (en) | Compressed pyridone compound, method for its preparation and use | |
| IL288104A (en) | Heterocyclic compounds, preparation methods and their use | |
| SG11202106706TA (en) | Heterocyclic compound intermediate, preparation method therefor and application thereof | |
| SG11202105850YA (en) | Diphenyl-like compound, intermediate thereof, preparation method therefor, pharmaceutical composition thereof and uses thereof | |
| EP3539963A4 (en) | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PREPARATION METHOD, INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND USE | |
| SG10202102822RA (en) | Alkynyl-substituted heterocyclic compound, preparation method therefor and medical use thereof | |
| IL245112A0 (en) | A compressed heterocyclic compound, a method for its preparation, a pharmaceutical preparation and its uses | |
| IL272446A (en) | Penta-condensed hexa-heterocyclic compounds, method for their preparation, drug combination and use thereof | |
| PT3580208T (pt) | Derivados de 2-(3-(1h-benzo[d]imidazol-1-il)propil)piperidin-3-ol e compostos relacionados como inibidores de prs para tratamento de, por exemplo, cancro | |
| EP3929185A4 (en) | CONDENSED CYCLIC COMPOUND CONTAINING NITROGEN, METHOD FOR PREPARATION AND USE | |
| PT3527552T (pt) | Derivado fundido tricíclico de -aminoácido, seu método de preparação, e sua utilização médica | |
| IL285378A (en) | A heterocyclic compound, a medical preparation containing it, a method for its preparation, and its use | |
| EP4006024A4 (en) | HETEROCYCLIC AMIDE COMPOUND, PREPARATION METHOD AND USE THEREOF | |
| IL276244A (en) | A pharmaceutical preparation for the eyes, a method for its preparation and its application | |
| EP3505517A4 (en) | FUSED HETEROCYCLIC DERIVATIVE, ITS PREPARATION METHOD AND ITS MEDICAL USE | |
| IL276430A (en) | A pharmaceutical compound, its cures, its formulations, and methods for its preparation and use | |
| EP3647313A4 (en) | SUBSTITUTED ARYLETHER COMPOUND, PROCESS FOR PREPARATION, PHARMACEUTICAL COMPOSITION AND USE | |
| HRP20200104T8 (hr) | Novi heterociklični spoj, metoda za pripremu istog, i farmaceutska kompozicija koja sadrži isto | |
| IL264511A (en) | Aromatic heterocyclic nitrogen compounds, a method for their preparation, their pharmaceutical compositions and their use | |
| ZA201804663B (en) | C-glycoside derivatives having fused phenyl ring or pharmaceutically acceptable salts thereof, method for preparing the same and pharmaceutical composition comprising the same | |
| GB202018729D0 (en) | Lycorine derivatives, pharmaceutical composite thereof and usage therefor | |
| ZA202100827B (en) | Novel compound, preparation method and application thereof | |
| EP3805212A4 (en) | 3-OXAZOLINONE COMPOUND, METHOD FOR PREPARING THEREOF, AND PHARMACEUTICAL USE THEREOF | |
| EP3608323A4 (en) | FUSED CYCLIC COMPOUND OF PYRANE, PREPARATION METHOD THEREOF AND USE THEREOF |